8 results about "Scaffold protein" patented technology

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

The application discloses application of SCAMP5 in treatment of autism spectrum disorder. The application research proves that, compared with a CON group, VPA-induced ASD rats have significant neurotransmitter release disorder and synapse signal path abnormality in hippocampus, overexpression of SCAMP5 protein can improve abnormal release of Glu, abnormal expression of scaffold protein Homer1b / c and downstream protein IP3R, and meanwhile, can relieve autism-like behaviors, space working memory and synapse development abnormality of ASD rats. The application provides a new target and a new potential drug for treatment of autism spectrum disorder, and provides a new idea for target treatment of ASD by in-depth exploration of potential path in pathogenesis of autism.

The present disclosure provides scaffold proteins that serve as framework regions for different sets of complementarity determining regions (CDRs) from source antibodies, where the source antibodies bind to different epitopes. The scaffold proteins find use in generating antigen binding polypeptides in single chain fragment variable (scFv) antibody format from a variety of antibodies of interest. These antigen binding polypeptides can have one or more advantageous properties as compared to a source antibody, such as, increased affinity, increased stability, increased expression in a cell, increased yield, etc. The sequence of a scaffold protein has a sequence identity of less than 68% to the sequence of the framework regions of the source antibody.

Systems and polypeptide complexes are provided that combine scaffold protein modules with a variety of effector modules, enabling comprehensive and versatile control at the protein, RNA, and DNA levels. In addition, uses of them in the modulation of gene expression and potential uses in the treatment of disease are provided.

The application discloses application of a polypeptide in preparation of a drug for treating or relieving PTSD. The application first discovers a specific scaffold protein FRMD5 of a protein isoform, the protein isoform can form a nuclear condensate, is combined with a group of unique protein partners (rich in GR chaperone cycle components and transcriptional co-regulators), and can reshape nuclear translocation, transcriptional activity and target gene expression of GR. An interfering peptide is designed aiming at the target, can regulate the nuclear translocation, transcriptional activity and target gene expression of GR, and can relieve stress response of a mouse. The application can be applied to preparation of a drug for treating or relieving PTSD.

This invention provides the application of ARF6 as a scaffold protein in the preparation of engineered extracellular vesicles, belonging to the field of biomedical technology. The application of ARF6 (SEQ ID NO.1) as a scaffold protein in the preparation of engineered extracellular vesicles (EVs) provided by this invention. This invention uses natural full-length ARF6 as a scaffold protein to prepare engineered EVs, fully leveraging its comprehensive advantages of short gene sequence, high editing and synthesis efficiency, strong loading capacity, and good versatility. It effectively overcomes the technical bottlenecks of existing EV drug delivery systems, such as low loading efficiency and complex construction processes, successfully constructing a highly efficient, universal, and safe protein and peptide drug delivery platform. The technical solution of this invention showed good anti-inflammatory effects in both cellular inflammation models and sepsis mouse models, indicating that this invention has significant clinical application value and industrialization prospects in the fields of drug delivery and disease treatment.

This invention provides the application of agents that inhibit NNMT binding to FGFR1 in the prevention and treatment of tumors. Through mutation analysis and interactomics analysis, it reveals a previously unknown, non-enzyme-dependent role of NNMT in promoting aerobic glycolysis in breast cancer. It discovers that NNMT binds to FGFR1 and acts as a scaffold protein, promoting phosphorylation of PKM2 and LDHA at Y105 and Y10 sites, respectively. By positioning the FGFR1 binding interface to the 140-154 amino acid region of NNMT, this invention designs a competitive cell-penetrating peptide, NNMT-15, which can disrupt the NNMT-FGFR1 interaction, reduce the phosphorylation levels of PKM2 and LDHA, inhibit glycolysis, and suppress proliferation in NNMT-high-expressing cancer cells and cancer-associated fibroblasts. These findings reveal NNMT as a dual-function metabolic regulator and establish the NNMT-FGFR1 scaffolding effect as a targeted therapeutic axis in glycolysis-dependent tumors.

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.